Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Employees

Sector

Pharmaceuticals

Calendar

06/08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/25/11	3.380 $	-2.59%	63,720
10/25/10	3.470 $	-0.86%	71,013
09/25/09	3.500 $	+2.04%	95,370
08/25/08	3.430 $	-0.58%	1,14,165
07/25/07	3.450 $	-1.43%	47,991

Delayed Quote Nasdaq, July 12, 2025 at 01:30 am IST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.380USD

Average target price

12.75USD

Spread / Average Target

+277.22%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 01:30:00 12/07/2025 am IST			5-day change	1st Jan Change
3.380 ^USD	-2.59%		-3.43%	+11.18%

20/06	PolyPid Ltd., Q1 2025 Earnings Call, May 14, 2025
18/06	Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating	MT

Capitalization	3.44Cr 2.95Cr 2.74Cr 2.55Cr 4.71Cr 295.45Cr 5.24Cr 33Cr 13Cr 138.33Cr 13Cr 13Cr 507.66Cr	P/E ratio 2025 *	-1.95x	P/E ratio 2026 *	-3.75x
Enterprise value	3.44Cr 2.95Cr 2.74Cr 2.55Cr 4.71Cr 295.45Cr 5.24Cr 33Cr 13Cr 138.33Cr 13Cr 13Cr 507.66Cr	EV / Sales 2025 *	-	EV / Sales 2026 *	7.37x
Free-Float	16.06%	Yield 2025 *	-	Yield 2026 *	-

PolyPid Ltd., Q1 2025 Earnings Call, May 14, 2025	20/06
Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating	18/06	MT
PolyPid Ltd. announced that it expects to receive $26.692799 million in funding	16/06	CI
PolyPid Ltd. - Special Call	11/06
PolyPid Says D-PLEX (100) Meets Primary Efficacy Endpoint In Phase 3 Trial	09/06	RE
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX100 Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints	09/06	CI
Roth Capital Initiates PolyPid at Buy With $9 Price Target	05/06	MT
PolyPid Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	14/05	CI
Polypid Q1 Net Income USD -8.3 Million	14/05	RE
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections	11/03	RE
PolyPid Ltd. Announces Successful Completion of Enrollment in Phase 3 SHield II Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections	11/03	CI
PolyPid Ltd. Auditor Raises 'Going Concern' Doubt	26/02	CI
PolyPid Ltd., Q4 2024 Earnings Call, Feb 12, 2025	12/02

Roth Capital Adjusts Price Target on PolyPid to $9 From $12, Maintains Buy Rating	18/06	MT
Roth Capital Initiates PolyPid at Buy With $9 Price Target	05/06	MT
HC Wainwright Adjusts Price Target on PolyPid to $11 From $14, Keeps Buy Rating	27/12	MT
HC Wainwright Initiates PolyPid With Buy Rating, Price Target is $16	12/23/12	MT
Barclays Downgrades PolyPid to Equalweight From Overweight, Adjusts Price Target to $2.50 From $22	07/22/07	MT

PolyPid Ltd. Share Price

Equities

PYPD

IL0011326795

Pharmaceuticals

Valuation: PolyPid Ltd.

Chart: PolyPid Ltd.

Latest news: PolyPid Ltd.

Last Transcript: PolyPid Ltd.

Analysts' recommendations: PolyPid Ltd.

Press Releases: PolyPid Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: PolyPid Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

PolyPid : Investor Presentation (7f2905)	11/07	PU
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results	17/06	AQ
PolyPid : Investor Presentation (88e1f7)	12/06	PU
PolyPid : Presentation of D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results – June 2025 (8dba8b)	09/06	PU
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX100 SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025	09/06	AQ

1 day	-2.59%
1 week	-3.43%
Current month	-4.25%
1 month	-2.31%
3 months	+36.29%
6 months	+9.03%
Current year	+11.18%

1 week	3.34	3.54
1 month	3.12	3.75
Current year	2.3	3.93
1 year	2.3	4.42
3 years	2.3	207
5 years	2.3	539.7
10 years	2.3	583.5

Manager	Title	Age	Since
Dikla Akselbrad CEO	Chief Executive Officer	51	01/07/2022
Jonny Missulawin DFI	Director of Finance/CFO	38	-
Ori Warshavsky COO	Chief Operating Officer	47	01/01/2022

Director	Title	Age	Since
Yechezkel Barenholz BRD	Director/Board Member	83	01/04/2008
Dikla Akselbrad BRD	Director/Board Member	51	08/08/2022
Jacob Harel CHM	Chairman	70	14/12/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
POLYPID LTD.	-2.59%	-3.43%	-16.95%	-97.63%	3.44Cr
ELI LILLY AND COMPANY	+0.30%	+1.58%	-15.11%	+139.53%	71TCr
JOHNSON & JOHNSON	-0.50%	+0.57%	+4.81%	-12.03%	38TCr
ABBVIE INC.	-1.31%	+1.67%	+13.27%	+25.60%	34TCr
NOVO NORDISK A/S	-3.64%	-2.74%	-54.62%	+8.25%	31TCr
ROCHE HOLDING AG	-2.36%	-1.23%	+1.86%	-21.34%	26TCr
NOVARTIS AG	-3.00%	-1.93%	-3.07%	+15.94%	24TCr
ASTRAZENECA PLC	-1.66%	+1.10%	-13.64%	-6.31%	22TCr
MERCK & CO., INC.	-0.79%	+3.00%	-35.36%	-11.60%	21TCr
AMGEN INC.	-1.70%	-1.00%	-9.17%	+19.17%	16TCr
Average	-1.72%	+0.41%	-12.80%	+5.96%	28.17TCr
Weighted average by Cap.	-1.30%	+0.64%	-11.78%	+36.74%

	2025 *	2026 *
Net sales	-	46.75L 40L 37.22L 34.67L 63.99L 40Cr 71.07L 4.46Cr 1.7Cr 19Cr 1.75Cr 1.72Cr 69Cr
Net income	-3Cr -2.57Cr -2.39Cr -2.23Cr -4.11Cr -257.6Cr -4.57Cr -29Cr -11Cr -120.6Cr -11Cr -11Cr -442.61Cr	-2.67Cr -2.28Cr -2.13Cr -1.98Cr -3.65Cr -228.99Cr -4.06Cr -25Cr -9.72Cr -107.21Cr -10Cr -9.81Cr -393.47Cr
Net Debt	-	-